{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:05:59Z","timestamp":1705277159726},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T00:00:00Z","timestamp":1490832000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatology Communications"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:p>We forecast the health and budgetary impact of hepatitis C (HCV) treatment on the Medicare program based on currently observed rates of treatment among Medicare and non\u2010Medicare patients and identify the impact of higher rates of treatment among non\u2010Medicare populations. We developed a computer microsimulation model to conduct an epidemiologic forecast, a budgetary impact analysis, and a cost\u2010effectiveness analysis of the treatment of HCV based on three scenarios: 1) no treatment, 2) continuation of current\u2010treatment rates, and 3) treatment rates among non\u2010Medicare patients increased to match that of Medicare patients. The simulated population is based on National Health and Nutrition Examination Survey data. HCV progression rates and costs were calculated in Surveillance, Epidemiology, and End Results Program Medicare 5% claims data from the Chronic Hepatitis Cohort Study and published literature. We estimate that 13.6% of patients with HCV in the United States are enrolled in Medicare, but 75% will enter Medicare in the next 20 years. Medicare patients were over 5 times as likely to be treated in 2014\u20102015 as other patients. Medicare paid over $9 billion in treatment costs in both 2015 and 2016 and will total $28.4 billion from 2017\u20102026. Increasing treatment rates among non\u2010Medicare patients would lead to 234,000 more patients being treated, reduce HCV mortality by 19%, and decrease Medicare costs by $18.6 billion from 2017\u20102026. We find that treatment remains cost\u2010effective under most assumptions, costing $31,718 per quality adjusted life year gained. <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: Medicare treats a disproportionately large share of HCV patients. Continued low rates of treatment among non\u2010Medicare HCV patients will result in both reduced and deferred treatment, shifting future treatment costs to Medicare while increasing overall medical management costs, morbidity, and mortality. (<jats:italic toggle=\"yes\">Hepatology Communications<\/jats:italic> 2017;1:99\u2010109)<\/jats:p>","DOI":"10.1002\/hep4.1031","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T06:29:54Z","timestamp":1490941794000},"page":"99-109","source":"Crossref","is-referenced-by-count":2,"title":["Potential epidemiologic, economic, and budgetary impacts of current rates of hepatitis C treatment in medicare and non\u2010medicare populations"],"prefix":"10.1097","volume":"1","author":[{"given":"John","family":"Wittenborn","sequence":"first","affiliation":[{"name":"NORC at the University of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Brady","sequence":"additional","affiliation":[{"name":"NORC at the University of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Dougherty","sequence":"additional","affiliation":[{"name":"NORC at the University of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rein","sequence":"additional","affiliation":[{"name":"NORC at the University of Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2017,3,30]]},"reference":[{"key":"hep41031-bib-0001-20240114","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.dld.2010.05.006","article-title":"Forecasting the morbidity and mortality associated with prevalent cases of pre\u2010cirrhotic chronic hepatitis C in the United States","volume":"43","year":"2011","journal-title":"Dig Liver Dis"},{"key":"hep41031-bib-0002-20240114","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/cid\/civ677","article-title":"Access to costly new hepatitis C drugs: medicine, money, and advocacy","volume":"61","year":"2015","journal-title":"Clin Infect Dis"},{"key":"hep41031-bib-0003-20240114","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/cid\/civ220","article-title":"The cost\u2010effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus","volume":"61","year":"2015","journal-title":"Clin Infect Dis"},{"key":"hep41031-bib-0004-20240114","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hep.26304","article-title":"The impact of timing and prioritisation on the cost\u2010effectiveness of birth\u2010cohort testing and treatment for hepatitis C virus in the United States","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"hep41031-bib-0005-20240114","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/hep.27736","article-title":"Cost\u2010effectiveness of hepatitis C treatment for patients in early stages of liver disease","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep41031-bib-0007-20240114","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S1473-3099(16)30005-6","article-title":"Access to treatment for hepatitis C virus infection: time to put patients first","volume":"16","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"hep41031-bib-0008-20240114","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","year":"2015","journal-title":"Ann Intern Med"},{"key":"hep41031-bib-0009-20240114","article-title":"Hepatitis C drugs top Medicaid spending, highlighting larger concerns","year":"2016","journal-title":"Politico"},{"key":"hep41031-bib-0010-20240114","article-title":"The cost of a cure: Medicare's role in treating hepatitis C","year":"2014","journal-title":"Health Affairs Blog"},{"key":"hep41031-bib-0013-20240114","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"hep41031-bib-0014-20240114","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"hep41031-bib-0015-20240114","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/hep.28430","article-title":"The burden of hepatitis C to the United States Medicare system in 2009: descriptive and economic characteristics","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep41031-bib-0016-20240114","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3111\/13696998.2015.1045423","article-title":"Costs and absence of HCV\u2010infected employees by disease stage","volume":"18","year":"2015","journal-title":"J Med Econ"},{"key":"hep41031-bib-0017-20240114","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","article-title":"The cost\u2010effectiveness of birth\u2010cohort screening for hepatitis C antibody in U.S. primary care settings","volume":"156","year":"2012","journal-title":"Ann Intern Med"},{"key":"hep41031-bib-0018-20240114","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","article-title":"Health\u2010state utilities and quality of life in hepatitis C patients","volume":"98","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"hep41031-bib-0019-20240114","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/gut.2005.064774","article-title":"Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C","volume":"55","year":"2006","journal-title":"Gut"},{"key":"hep41031-bib-0020-20240114","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1001\/archinte.164.21.2377","article-title":"Health values of patients with chronic hepatitis C infection","volume":"164","year":"2004","journal-title":"Arch Intern Med"},{"key":"hep41031-bib-0021-20240114","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1017\/S0266462305050075","article-title":"Effectiveness and cost\u2010effectiveness of initial combination therapy with interferon\/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security","volume":"21","year":"2005","journal-title":"Int J Technol Assess Health Care"},{"key":"hep41031-bib-0022-20240114","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1572-0241.2005.40976.x","article-title":"Estimation of utilities for chronic hepatitis C from SF\u201036 scores","volume":"100","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"hep41031-bib-0023-20240114","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","article-title":"Toward consistency in cost\u2010utility analyses: using national measures to create condition\u2010specific values","volume":"36","year":"1998","journal-title":"Med Care"},{"key":"hep41031-bib-0024-20240114","article-title":"The cost of a cure: revisiting Medicare Part D and hepatitis C drugs","year":"2016","journal-title":"Health Affairs Blog"},{"key":"hep41031-bib-0025-20240114","article-title":"Sovaldi is expensive, but this drug cost N.C. Medicaid even more","year":"2015","journal-title":"Triangle Business Journal"},{"key":"hep41031-bib-0026-20240114","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/jvh.12506","article-title":"Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network","volume":"23","year":"2016","journal-title":"J Viral Hepat"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep4.1031","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/02009842-201704000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T16:01:45Z","timestamp":1705248105000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/02009842-201704000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,30]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.1031","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"value":"2471-254X","type":"print"},{"value":"2471-254X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,30]]}}}